Cytori Therapeutics Inc Stock Nasdaq
Stocks
US23283K1051
Biotechnology & Medical Research
| Market Cap | 25.74M 22.5M 20.76M 19.13M 36.07M 2.48B 36.87M 248M 97.59M 1.21B 96.68M 94.56M 4.18B | P/E 2026 * |
-0.95x | P/E 2027 * | -1.56x |
|---|---|---|---|---|---|
| Enterprise Value | 25.74M 22.5M 20.76M 19.13M 36.07M 2.48B 36.87M 248M 97.59M 1.21B 96.68M 94.56M 4.18B | EV / Sales 2026 * |
4.09x | EV / Sales 2027 * | 1.34x |
| Free-Float |
98.02% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Cytori Therapeutics Inc
| 1 day | -1.85% |
| Manager | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 64 | 02/04/2014 |
Andrew Sims
DFI | Director of Finance/CFO | 52 | 06/02/2020 |
Daniel Ortega
CTO | Chief Tech/Sci/R&D Officer | - | 21/10/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Marc Hedrick
BRD | Director/Board Member | 64 | 01/10/2002 |
Richard Hawkins
CHM | Chairman | 77 | 25/01/2018 |
| Director/Board Member | 66 | 01/01/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.85% | -29.07% | - | - | 25.74M | |
| +3.90% | -0.39% | +386.06% | +593.85% | 39.58B | |
| -1.70% | +4.46% | +5.93% | +60.25% | 34.69B | |
| -2.01% | -0.76% | +28.41% | -8.01% | 34.42B | |
| +0.06% | +0.34% | +2.38% | +34.38% | 27.11B | |
| +0.46% | -3.49% | - | - | 16.21B | |
| -0.04% | -0.09% | +72.42% | +115.55% | 15.36B | |
| +1.12% | +1.91% | +14.54% | +19.16% | 14.05B | |
| 0.00% | +1.36% | +18.43% | -30.79% | 13.02B | |
| -0.08% | -3.01% | +1,282.83% | +635.80% | 11.76B | |
| Average | -0.01% | +0.04% | +226.37% | +177.52% | 22.91B | |
| Weighted average by Cap. | +0.24% | +0.36% | +174.57% | +186.15% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 6.3M 5.5M 5.08M 4.68M 8.82M 606M 9.02M 60.68M 23.87M 297M 23.64M 23.12M 1.02B | 19.14M 16.73M 15.44M 14.23M 26.82M 1.84B 27.41M 184M 72.57M 903M 71.88M 70.31M 3.11B |
| Net income | -26.8M -23.42M -21.61M -19.92M -37.55M -2.58B -38.38M -258M -102M -1.26B -101M -98.44M -4.35B | -18.45M -16.13M -14.88M -13.72M -25.86M -1.78B -26.43M -178M -69.96M -870M -69.31M -67.79M -3B |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
